<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02022306</url>
  </required_header>
  <id_info>
    <org_study_id>0094</org_study_id>
    <nct_id>NCT02022306</nct_id>
  </id_info>
  <brief_title>TD-6450 SAD and MAD in Healthy Subjects</brief_title>
  <official_title>A Double-Blinded, Randomized, Placebo-Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of TD-6450, a NS5A Inhibitor, in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance Biopharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study consists of two parts, Parts A and B. Part A is a single ascending dose (SAD)&#xD;
      study in healthy subjects. Part B is a multiple ascending dose (MAD) study in healthy&#xD;
      subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>28 days max</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>28 days max</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>28 days max</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>28 days max</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>28 days max</time_frame>
    <description>Pharmacokinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food effect on AUC value</measure>
    <time_frame>15 days max</time_frame>
    <description>Measure difference between fasted and fed doses</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>SAD TD-6450</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single ascending dose (Part A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MAD TD-6450</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple ascending dose (Part B)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Food effect of TD-6450</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Food effect will be assessed in Part A (SAD) of this study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-6450</intervention_name>
    <arm_group_label>Food effect of TD-6450</arm_group_label>
    <arm_group_label>MAD TD-6450</arm_group_label>
    <arm_group_label>SAD TD-6450</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>MAD TD-6450</arm_group_label>
    <arm_group_label>SAD TD-6450</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is a female of non-childbearing potential or male, who is healthy, nonsmoking,&#xD;
             and 18 to 60 years old, inclusive, at screening. Females are considered to be of non&#xD;
             childbearing potential if they have had a hysterectomy or tubal ligation&#xD;
             (documentation required) or are postmenopausal (amenorrheic for at least 2 years) with&#xD;
             a follicle stimulating hormone (FSH) level &gt;40 IU/L&#xD;
&#xD;
          -  Subject has a body mass index 18 to 30 kg/m2, inclusive, and weighs at least 50 kg.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has evidence or history of clinically significant allergic (except for&#xD;
             untreated, asymptomatic, seasonal allergies at time of dosing), hematological,&#xD;
             endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, or&#xD;
             neurological disease.&#xD;
&#xD;
          -  Subject has an estimated creatinine clearance of &lt;90 mL/min at Screening or Day -1,&#xD;
             calculated using the Cockcroft-Gault equation.&#xD;
&#xD;
          -  Subject has participated in another clinical trial of an investigational drug (or&#xD;
             medical device) within 60 days prior to Screening, or is currently participating in&#xD;
             another trial of an investigational drug (or medical device).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Theravance Biopharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ICON Development Solutions</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 17, 2013</study_first_submitted>
  <study_first_submitted_qc>December 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 27, 2013</study_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

